Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

NICE Recommends T-DXd for HER2-Low Metastatic Breast Cancer

18 September 2026 · By · Wire by Fusion42

Published

18 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United Kingdom

◆ Source

Read at cancernetwork.com →

◆ Verified

Fusion42 · 18 September 2026 · Fusion42 review

NICE has recommended trastuzumab deruxtecan (T-DXd) for reimbursement in England for adults with unresectable or metastatic HER2-low breast cancer, potentially benefiting over 1000 patients annually. This aligns England with access in Scotland and 26 other European countries, based on strong efficacy and safety data from the DESTINY-Breast04 trial.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face a newly opened market in England for HER2-low metastatic breast cancer treatment. You need to engage NHS channels quickly to capture patient access and support uptake following NICE's endorsement.

◆ Coverage

1 source · 18 Sep 2026

◆ Related on Wire

◆ Topics

Biotechcancerregulatory-approvalbreast-cancerHER2-lowtrastuzumab-deruxtecan